

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MASON GROUP HOLDINGS LIMITED**

**茂宸集團控股有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 273)**

### **APPOINTMENT OF DIRECTORS AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES**

#### **APPOINTMENT OF DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”) of Mason Group Holdings Limited (the “**Company**”) is pleased to announce that Mr. Cao Lu (“**Mr. Cao**”) has been appointed as an executive Director with effect from 1 December 2018 and Mr. Wang Cong (“**Mr. Wang**”) has been appointed as an independent non-executive Director with effect from 1 December 2018. The biographical details of each of Mr. Cao and Mr. Wang are set out as follows:

#### **Mr. Cao**

Mr. Cao, aged 37, obtained his Master’s degree in Business Administration from Nankai University. He joined the Company as the managing director of the internal audit department of the Company in September 2017 and has been re-designated as the senior country officer for China of the Company since 1 November 2018. He is also a director of Raiffeisen Privatbank Liechtenstein AG, a wholly-owned subsidiary of the Company. Mr. Cao is primarily responsible for developing business partner relationships to support the Company’s financial platform businesses and for implementing strategic plans to expand the businesses geographically. Mr. Cao also drives diversified marketing plans on brand building, products and services and handles client acquisition and maintenance for the China market.

Mr. Cao has over 10 years of experience in investment banking, direct investment, mergers and acquisition in China. He has in-depth understanding of the China market with extensive knowledge about capital markets and investment banking.

Mr. Cao entered into a service agreement with the Company for a term of three years commencing on 1 December 2018 subject to retirement from office and re-election at the first annual general meeting of the Company after his appointment and subsequently subject to retirement from office by rotation and re-election at the annual general meeting of the Company and vacation from office in accordance with the articles of association of the Company.

Mr. Cao is entitled to a remuneration of HK\$2,280,000 per annum (including salary as the senior country officer for China of the Company and director's fee) plus discretionary bonus in respect of his appointment which has been determined by reference to his background, qualifications, experience, level of responsibilities undertaken with the Company and prevailing market conditions.

Mr. Cao has not at any time during the three years preceding the date of this announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas. Save as disclosed above, Mr. Cao also confirms that he does not hold other positions with the Company or any other member of the Company and its subsidiaries.

As at the date of this announcement, Mr. Cao confirms that he does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and has no relationships with any directors, senior management, substantial shareholders, or controlling shareholders of the Company.

The Board is not aware of any other information required to be disclosed pursuant to paragraphs (h) to (v) of Rules 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”) or any other matters ought to be brought to the attention of the shareholders of the Company

### **Mr. Wang**

Mr. Wang, aged 28, graduated from National University of Singapore with a Bachelor's Degree in Engineering Science in 2013. In 2014, he obtained his Master's Degree in Aeronautics from California Institute of Technology. Since 2014, Mr. Wang has joined a research group in Aeronautics at California Institute of Technology and is working towards a Doctor of Philosophy (PhD) in Aeronautics. He is a co-inventor of three patents under application<sup>Note</sup> filed with the United States Patent and Trademark Office, including medical device and fluid dynamic.

Mr. Wang entered into a Letter of appointment with the Company for a term of three years commencing on 1 December 2018 subject to retirement from office and re-election at the first annual general meeting of the Company after his appointment and subsequently subject to retirement from office by rotation and re-election at the annual general meeting of the Company and vacation from office in accordance with the articles of association of the Company.

Mr. Wang is entitled to a remuneration of HK\$240,000 per annum for his appointment as an independent non-executive director, which was determined with reference to the duties and responsibilities of an independent non-executive Director and the prevailing market conditions.

Mr. Wang has not at any time during the three years preceding the date of this announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas. Mr. Wang also confirms that he does not hold other positions with the Company or any other member of the Company and its subsidiaries.

Mr. Wang has confirmed that he meets the independence criteria set out in Rule 3.13 of the Listing Rules.

As at the date of this announcement, Mr. Wang confirms that he does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and has no relationships with any directors, senior management, substantial shareholders, or controlling shareholders of the Company.

The Board is not aware of any other information required to be disclosed pursuant to paragraphs (h) to (v) of Rules 13.51(2) of the Listing Rules or any other matters ought to be brought to the attention of the shareholders of the Company.

## **CHANGE IN THE COMPOSITION OF BOARD COMMITTEES**

The Board announces that Mr. Wang has been appointed as a member of each of the audit committee, remuneration committee and nomination committee of the Company with effect from 1 December 2018.

The Board would like to extend its warmest welcome to Mr. Cao and Mr. Wang to join the Board.

By order of the Board  
**Mason Group Holdings Limited**  
**KO Po Ming**  
*Chairman and Chief Executive Officer*

Hong Kong, 30 November 2018

*As at the date of this announcement, the Board comprises:*

*Executive Directors:*

Mr. Ko Po Ming (*Chairman and Chief Executive Officer*)  
Mr. Chang Tat Joel  
Ms. Lui Choi Yiu, Angela  
Ms. Fu Yau Ching, Shirley

*Non-executive Director:*

Ms. Hui Mei Mei, Carol

*Independent Non-executive Directors:*

Mr. Tian Ren Can  
Ms. Kan Lai Kuen, Alice  
Mr. Chen Wai Chung, Edmund

*Note:*

- (1) Patent application no. 14/947767 filed on 20 November, 2015 “Micro-Needle Drug Delivery Systems”
- (2) Patent application no. 15/411544 filed on 20 January, 2017 “Vertical Carbon Nanotube and Lithium Ion Battery Chemistries, Articles, Architectures and Manufacture”
- (3) Patent application no. 15/663595 filed on 28 July, 2017 “System, Methods, and Apparatuses for Reducing Hydrodynamic Frictional Drag